Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultra-rare genetic diseases, announced its upcoming participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Emil Kakkis, M.D., Ph.D., will engage in a fireside chat on Tuesday, June 10, 2025, at 10:00 a.m. ET. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at ir.ultragenyx.com/events-presentations.

News Market Reaction – RARE

+0.58%

1 alert

+0.58% News Effect

On the day this news was published, RARE gained 0.58%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. ET.

The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com

FAQ

When is Ultragenyx (RARE) presenting at the Goldman Sachs Healthcare Conference 2025?

Ultragenyx will present on Tuesday, June 10, 2025, at 10:00 a.m. ET.

Who will represent Ultragenyx at the Goldman Sachs Healthcare Conference?

Emil Kakkis, M.D., Ph.D., the company's CEO, will participate in a fireside chat at the conference.

How can I watch Ultragenyx's presentation at the Goldman Sachs conference?

The presentation can be accessed via live and archived webcast through Ultragenyx's website at ir.ultragenyx.com/events-presentations.

What is Ultragenyx's (RARE) main business focus?

Ultragenyx is a biopharmaceutical company focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases.